Seres Therapeutics Newsroom

This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

BenzingaOct 24 07:50 ET

J.P. Morgan Downgrades Seres Therapeutics(MCRB.US) to Sell Rating

Moomoo NewsOct 23 18:31 ET · Ratings

Seres Cut to Underweight by JP Morgan on Vowst Sale

Seeking AlphaOct 23 17:48 ET

Seres Therapeutics Downgraded to Underweight From Neutral at JPMorgan

TipRanksOct 23 17:40 ET

Seres Therapeutics Gains Amid Takeover Speculation

Seeking AlphaOct 10 11:59 ET

Seres Therapeutics Rumor Highlighted in Betaville Blog

TipRanksOct 10 11:50 ET

Express News | Watching Seres Therapeutics; Traders Circulate M&A Blog Unconfirmed Rumor That Nestle Has Said To Have Made A Bid Between $6.90-$7.20/Share

BenzingaOct 10 11:41 ET

Institutions Along With Retail Investors Who Hold Considerable Shares InSeres Therapeutics, Inc. (NASDAQ:MCRB) Come Under Pressure; Lose 12% of Holdings Value

Yahoo FinanceOct 8 09:34 ET

Seres Therapeutics Files Registration for Resale of Shares by Societe Des Produits Nestle

MT NewswiresOct 1 17:23 ET

Express News | Seres Therapeutics Files Prospectus Related to Resale,From Time to Time, of up to 14.3 Mln Shares of Common Stock by Selling Stockholder- SEC Filing

ReutersOct 1 16:48 ET

Express News | Mkt Capital: Request Seres Board Immediately Provide Stockholders With Facts for Its Engagement With Nestlé Ahead of Sept 30 Closing of Vowst Sale

ReutersSep 27 15:29 ET

Express News | Mkt Capital, Other Seres Therapeutics Stockholders: Express Concern on Report That Co Rebuffed Outright Takeover Offer From Nestlé

ReutersSep 27 15:29 ET

Express News | Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

ReutersSep 27 15:26 ET

Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

BusinesswireSep 27 15:26 ET

12 Health Care Stocks Moving In Thursday's After-Market Session

BenzingaSep 26 16:31 ET

Seres Therapeutics Stockholders Approve Sale of VOWST to Nestlé Health Science; Sale Expected to Close on September 30

GlobeNewswireSep 26 16:01 ET

Express News | Seres Therapeutics Stockholders Approve Sale of Vowst™ to Nestlé Health Science; Sale Expected to Close on September 30

ReutersSep 26 16:01 ET

Seres Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow JonesSep 13 14:48 ET · Ratings

Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity

Dow JonesSep 13 14:48 ET · Ratings

Seres Therapeutics Analyst Ratings

BenzingaSep 13 14:36 ET · Ratings